cefpodoxime proxetil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 555 | 87239-81-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Prodrug for cefpodoxime
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.30 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 17.93 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 52 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 7, 1992 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cystitis bacterial | 29.23 | 24.23 | 5 | 1430 | 231 | 63487356 |
| Arthritis reactive | 26.38 | 24.23 | 5 | 1430 | 413 | 63487174 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pyrexia | 27.54 | 21.73 | 55 | 1912 | 678654 | 79063767 |
| Clostridium difficile colitis | 26.98 | 21.73 | 14 | 1953 | 32269 | 79710152 |
| Arthritis reactive | 24.02 | 21.73 | 5 | 1962 | 609 | 79741812 |
| Cystitis bacterial | 23.30 | 21.73 | 5 | 1962 | 705 | 79741716 |
| Meningoencephalitis bacterial | 22.07 | 21.73 | 4 | 1963 | 236 | 79742185 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DD13 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
| ATC | J01DD64 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
| FDA CS | M0003827 | Cephalosporins |
| FDA EPC | N0000175488 | Cephalosporin Antibacterial |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute otitis media | indication | 3110003 | |
| Gonorrhea | indication | 15628003 | DOID:7551 |
| Haemophilus Influenzae Acute Otitis Media | indication | 19021002 | |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Acute gonococcal urethritis | indication | 29864006 | |
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Streptococcal tonsillitis | indication | 41582007 | |
| Gonorrhea of rectum | indication | 42746002 | |
| Bacterial pneumonia | indication | 53084003 | DOID:874 |
| Klebsiella cystitis | indication | 60867007 | |
| Acute maxillary sinusitis | indication | 68272006 | DOID:2050 |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Acute bacterial sinusitis | indication | 75498004 | |
| Tonsillitis | indication | 90176007 | DOID:10456 |
| Acute Moraxella catarrhalis bronchitis | indication | 195722003 | |
| Acute bacterial bronchitis | indication | 233598009 | |
| Pneumococcal pneumonia | indication | 233607000 | |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Streptococcus pyogenes infection | indication | 302809008 | |
| Bacterial urinary infection | indication | 312124009 | |
| Infective otitis media | indication | 312218008 | |
| Pharyngitis | indication | 405737000 | DOID:2275 |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Acute exacerbation of chronic bronchitis | indication | 425748003 | |
| Moraxella Catarrhalis Acute Otitis Media | indication | 703469002 | |
| Streptococcus Pneumoniae Bronchitis | indication | ||
| Staphylococcus Saprophyticus Urinary Tract Infection | indication | ||
| Pneumococcal Acute Otitis Media | indication | ||
| Haemophilus Influenzae Chronic Bronchitis | indication | ||
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Factor II deficiency | contraindication | 73975000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Skin infections caused by Staphylococcus intermedius | Indication |
| Dogs | Skin infections caused by Staphylococcus aureus | Indication |
| Dogs | Skin infections caused by Streptococcus canis | Indication |
| Dogs | Skin infections caused by Escherchia coli | Indication |
| Dogs | Skin infections caused by Pasteurella multocida | Indication |
| Dogs | Skin infections caused by Proteus mirabilis | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Simplicef | Zoetis Inc. | 1 |
| Cefpodoxime Proxetil Tablets | Dechra Veterinary Products LLC | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.1 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4020567 | VUID |
| N0000148269 | NUI |
| D00920 | KEGG_DRUG |
| 20489 | RXNORM |
| C0108938 | UMLSCUI |
| CHEBI:3504 | CHEBI |
| CHEMBL1201016 | ChEMBL_ID |
| C053267 | MESH_SUPPLEMENTAL_RECORD_UI |
| C053268 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2TB00A1Z7N | UNII |
| 6526396 | PUBCHEM_CID |
| DB01416 | DRUGBANK_ID |
| 4381 | MMSL |
| 57686 | MMSL |
| d00095 | MMSL |
| 003727 | NDDF |
| 003728 | NDDF |
| 387534007 | SNOMEDCT_US |
| 96049003 | SNOMEDCT_US |
| 96050003 | SNOMEDCT_US |
| C0055011 | UMLSCUI |
| CHEMBL1672 | ChEMBL_ID |
| 4020567 | VANDF |
| 6123 | INN_ID |
| 80210-62-4 | SECONDARY_CAS_RN |
| 6335986 | PUBCHEM_CID |
| 10780 | IUPHAR_LIGAND_ID |
| 7R4F94TVGY | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cefpodoxime Proxetil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5438 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Cefpodoxime Proxetil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5439 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 26 sections |
| CEFPODOXIME PROXETIL | Human Prescription Drug Label | 1 | 16714-394 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 24 sections |
| CEFPODOXIME PROXETIL | Human Prescription Drug Label | 1 | 16714-394 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 24 sections |
| CEFPODOXIME PROXETIL | Human Prescription Drug Label | 1 | 16714-395 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 24 sections |
| CEFPODOXIME PROXETIL | Human Prescription Drug Label | 1 | 16714-395 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 16714-402 | GRANULE, FOR SUSPENSION | 50 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 16714-402 | GRANULE, FOR SUSPENSION | 50 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 16714-403 | GRANULE, FOR SUSPENSION | 100 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 16714-403 | GRANULE, FOR SUSPENSION | 100 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-083 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-084 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
| CEFPODOXIME PROXETIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-393 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
| CEFPODOXIME PROXETIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-393 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 64980-402 | GRANULE, FOR SUSPENSION | 50 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 64980-402 | GRANULE, FOR SUSPENSION | 50 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 64980-403 | GRANULE, FOR SUSPENSION | 100 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 64980-403 | GRANULE, FOR SUSPENSION | 100 mg | ORAL | ANDA | 23 sections |
| CEFPODOXIME PROXETIL | Human Prescription Drug Label | 1 | 65862-095 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
| CEFPODOXIME PROXETIL | Human Prescription Drug Label | 1 | 65862-096 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 65862-140 | GRANULE, FOR SUSPENSION | 50 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 65862-140 | GRANULE, FOR SUSPENSION | 50 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 65862-141 | GRANULE, FOR SUSPENSION | 100 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 65862-141 | GRANULE, FOR SUSPENSION | 100 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 67877-559 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 67877-560 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 67877-878 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
| Cefpodoxime Proxetil | Human Prescription Drug Label | 1 | 67877-879 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
| CEFPODOXIME PROXETIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-2742 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 24 sections |
| Cefpodoxime Proxetil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-3441 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |